LifeLines

Your Story is Our Story

When it comes to CRISPR-based gene therapies, size isn’t just a detail—it’s a game-changer. Traditional gene editing relies on the Cas9 enzyme, a powerful tool but one with delivery and targeting challenges. Mammoth Biosciences is rewriting the rules with ultracompact Cas enzymes, enabling more precise in-vivo delivery, even in hard-to-reach tissues. Co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna, Ph.D., the company is moving beyond traditional gene splicing to develop more precise, controlled, and potentially safer therapies.

Join us for our video series, Your Story is Our Story, featuring groundbreaking achievements and exclusive behind-the-scenes looks at pioneering companies shaping the future of life science in California.